Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement and robust biopharma demand.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.